Videregen’s board is made up of experienced professionals with a wealth of experience in commercialising bio-technology innovation.
Martin Hunt – Chairman
Martin Hunt – Chairman Martin has over 30 years’ experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising (>£40m) in the life science sector. His previous roles include CEO of biomaterials company Tissue Science Laboratories plc which he took from start-up, through angel capital and a listing on London’s AiM market to trade sale to Covidien in May 2008. Since the acquisition, Martin has acted as Chairman of Orthox, Deputy Chairman of Trophos SA and Chairman of DySIS medical. He is also Deputy Chairman of MDY Limited. In the public sector, Martin is Programme Director of the NIHR translational funding programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board
Dr Steve Bloor – CEO
Steve has over 20 years’ experience in medical devices and regenerative medicine, with expertise and leadership skills in strategic R&D, clinical compliance and regulation. He has worked in US multinationals (J&J, Covidien) and UK start-up companies. Steve was formerly CSO at Tissue Science Laboratories and was behind the development of TSL’s unique tissue replacement technology. Following Covidien’s $80m acquisition of TSL in 2008, he became VP R&D at Covidien. Steve founded Videregen Ltd in 2011 as a spin-out from Northwick Park Institute for Medical Research to develop and commercialise the Institute’s advanced organ replacement technologies.
Doug Quinn – CFO
Doug is an experienced finance director having spent the last 15 years working with early stage technology businesses. Together with his knowledge and experience of financial management and corporate governance Doug has considerable corporate transaction experience having been involved in a number of M&A transactions, including a medtech AIM float.
Dr Cathy Prescott – NED
Cathy brings over 20 years’ experience working within the life sciences sector including academia, business, financial services and venture capital. She is the Founder Director of Biolatris Ltd. and Co-founder Director of Quartet Innovation Partners Ltd. Cathy is a member of the Worcester Polytechnic Institute (USA) Life Sciences Advisory Board and a member of the Board of Trustees for the charity The International Medical Education Trust 2000. Cathy is involved in developing and implementing innovative finance and business models for emerging and disruptive sectors. She is a respected opinion leader within the stem cell and regenerative medicine business sector, and co-editor of the book ‘The Delivery of Regenerative Medicines and their Impact on Healthcare’ (CRC Press). She is also a mentor to the Centre for Entrepreneurial Learning summer business school (Cambridge University), Senior Associate for the Masters in Bioscience (Cambridge University), PhD examiner (Cambridge University) and mentor to the Royal Academy of Engineering entrepreneur awards scheme. Cathy is the author of peer-reviewed publications and invited speaker at national and international conferences serving both the life-science and financial services sectors (Actuarial Profession, insurer and underwriting conferences).
Dr Marc d’Abbadie – NED
Marc represents SPARK Impact and the North West Fund for Biomedical on the Videregen Board. Marc has a wealth of entrepreneurial experience and biomedical venture investment knowledge and was previously an investment manager at London-based Inventages, which manages one of the world’s largest life-science focused venture capital funds with assets of $1.5b.
Dr Robert Hollamby – NED
Robert is our lead Angel investor and represents the London Business Angels on the Videregen Board. Robert founded in 1996 the Total Healthcare Group, a specialist consultancy providing services to large and small biopharma companies in the area of pricing and reimbursement. The group comprising Total Healthcare Solutions and Total Healthcare Media, was a pioneer in this field and provided coverage of over 40 markets globally to become a top 3 player; it was acquired in 2010 by United BioSource Corporation (UBC, part of Medco Inc. The group was subsequently acquired along with other assets by Symphony Technology Group (STG), a West Coast private equity group, to form Evidera. Robert is now Executive in Residence for STG and has a number of other commercial activities. Robert originally qualified as a surgeon before embarking on a successful business career and brings with him a wealth of experience and knowledge to the Videregen Board.